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Caspases: Intracellular Minireview
Signaling by Proteolysis
of the protein, sometimes in inactivation, but never in
degradation since their substrate specificity distin-
guishes the caspases as among the most restricted of
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²Department of Molecular Oncology endopeptidases. Caspase 1 is remarkably specific for
Genentech Inc. the precursors of IL-1b and IL-18 (interferon-g-inducing
South San Francisco, California 94080 factor), making a single initial cut in each procytokine
that activates them and allows exit from the cytosol.
Ectopic expression of caspase 1 in some cells can result
The discovery of a novel proteolytic network in the cyto- in apoptosis, but a role in developmentally programmed
sol of metazoan cells comes as a surprise to a field that cell death is unlikely given the normal phenotype of
previously considered intracellular proteolysis to mainly knockout mice (see for example, Ghayur et al., 1997).
be a mechanism to process antigen or remove effete Processing of thecaspase 1 precursor, required for acti-
proteins. The network, supported by caspases, a family vation, is rarely seen in experimental models of apop-
of cysteine proteases that specifically cleave proteins tosis, and thus, though it is clearly required for activation
after Asp residues, involves limited proteolysis of a of the cytokines mentioned above, the role of this cas-
growing numberof cellular substrates. It is not surprising pase in apoptosis, if any, is still uncertain. The close
that a signaling pathway utilizes proteolysis, for this is relationship in sequence identity and predicted sub-
the essence of the blood coagulation cascade. What is strate specificity of caspases 4 and 5 implicate them as
surprising is that the caspase pathway takes place in effectors of cytokine activation, possibly as upstream
the interior of a cell. Caspase precursors are usually activators of caspase 1 itself.
activated at internal conserved Asp residues, with the Whereas caspase 1 (and possibly 4 and 5) is primarily
result that most activated caspases can process their involved in procytokine activation, othercaspases, nota-
own and other caspase zymogens given sufficient time bly 2, 3, 6, 7, 8, and 10, are considered to promote
and a high enough concentration in vitro (see for exam- pathways to apoptosis. This conclusion is based largely
ple, Srinivasula et al., 1996). This suggests a cascade on the following observations: (1) thezymogens are seen
mechanism for transmission of signals, but the extent to be processed during apoptosis, or in vitro models of
to which this happens in vivo is currently an enigma, apoptosis, and (2) at least in vitro, they cut proteins
and a fertile area of research. whose cleavage is associated with apoptotic cell death.
The caspases seem tobe a developmentof multicellu- So far, about a dozen proteins have been shown to
lar organisms, and in humans at least seven of the ten be specifically cleaved during apoptosis. It is relatively
currently known family members participate in one of
simple to demonstrate which clips are caused by cas-
two distinct signaling pathways: (1) activation of proin-
pases (it turns out to be almost all of them) through
flammatory cytokines, and (2) promotion of apoptotic
analysis of the cleavage site, but more difficult to deter-
cell death. Recent publications have reviewed the dis-
mine which caspases are responsible in vivo. For exam-
covery of the caspases and some of their substrates
ple, the first protein discovered to be cleaved by cas-
(see for example, Nicholson, 1996; Zhivotovsky et al.,
pases during apoptosis, poly(ADP-ribose) polymerase,
1997), and here we provide an update that focuses on
is a substrate for most caspases under somewhat ex-the initiation, transmission, and regulation of caspase
treme conditions in vitro, but in vivo is probably targetedactivity.
by caspases 3 and 7. Thus, by combining in vivo obser-Structure, Mechanism, and Specificity
vations with in vitro tests on suspect proteins, one canIn common with other protease zymogens, generation
recognize distinctions in substrate specificity within theof an active form requires limited proteolysis (Figure
caspase family that fit remarkably closely to the S42S11). For the caspases, this results from cleavage in an
subsite preferences deduced from synthetic peptidicinterdomain linker segment to give a heterodimeric en-
substrates (Talanian et al., 1997; Thornberry et al., 1997)zyme, with both chains containing essential compo-
(Figure 2).nents of the catalytic machinery. Sometimes an N-termi-
Singularly important in this context is that caspasenal peptide, not required for enzyme activity, is released.
zymogens are themselves substrates for caspases, andThe role of the N peptide is only known for caspases 1
inspection of the individual interdomain linker in eachand 8, where it behaves as a protein interaction domain
zymogen reveals target sites that confirm the preferenceto modulate activation.
of some caspases to activate others in a hierarchicalThe 3-D structures of caspases 1 and 3 reveal two
relationship. Thus, pathways exist to transmit signalsheterodimers interacting via the small chains, providing
via sequential caspase activations, and this has beeneach molecule with two active sites. The primary recog-
most extensively examined in apoptosis.nition pocket (S1) is well adapted to accept an Asp side
Caspases Are Required for Apoptosischain of the substrate, and additional pockets (S2±S4)
A key to apoptosis is the discovery in many laboratoriesdistinguish the caspases from each other (Figure 2).
that, irrespective of the lethal stimulus, death results inCaspases cleave a number of cellular proteins, and
the same apoptotic morphology that includes cell andthe process is one of limited proteolysis where a small
organelle dismantling and packaging, DNA cleavage tonumber of cuts, usually only one, are made in interdo-
main regions. Sometimes cleavage results in activation nucleosome-sized fragments, and caspase-mediated
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Figure 1. Schematic of a Processed Caspase
The active form of a caspase consists of large and small chains
released from a precursor by proteolysis. A linker segment flanked
by Asp resideus, and an N-terminal polypeptide (sometimes known
as the prodomain) is also released from several caspases during
activation, as in the example of caspase-1 shown above. The
N-peptide is not conserved between caspases, but the two chains
(shown in black) that fold to form the catalytic site contain extensive
identities throughout the family.
cleavage of the same cellular proteins. A fascinating
Figure 3. Life and Death Decisions
demonstration of the importance of caspases was pro-
Death may be signaled by direct ligation of receptors at the cell
vided by engaging the death pathway through expres- surface, which leads to the activation of initiator caspases (8 or 10).
sion of the pro-apoptotic factor Bax in cells bathed in the These caspases then, directly or indirectly, activate the ªexecutioner
presumptive cell-permeable caspase inhibitor Z-VAD- caspasesº (3, 6, and 7). Alternatively, irreparable damage to the
genome caused by mutagens, pharmaceuticals that inhibit DNAfluoromethyl ketone (Xiang et al., 1996). Though death
repair, or ionizing radiationÐtransmitted by a currently unknownwas delayed, it was not abolished despite complete
mechanismÐengages the same executioner caspases. The latterinhibition of caspase activity. However, the resulting
events progress through a pathway that is regulated by members
death morphology was not apoptotic but more reminis- of the Bcl2/Bax family, and which may result in the release of pro-
cent of necrosis. In contrast, ligation of the death recep- apoptotic factors from mitochondria, for example (see for example,
Kroemer et al., 1997; Liu et al., 1997). Input is integrated by a hypo-tor Fas on cells expressing the viral caspase inhibitor
thetical entityÐthe ªapostatº (Bredesen, 1996)Ðthat makes deci-CrmA had no effectÐthe cells were completely vibrant
sions for the fate of the cell. The search for chemical identity of thein otherwise lethal levels of Fas antibody and exhibited
apostat represents somewhat of a ªholy grailº in cell death research.no signs of apoptosis or other forms of death (Tewari
et al., 1995). The explanation for the different outcomes
cuts to the heart of the death pathway. In initiation of Commitment and Caspase Activation
death via Fas, the first signal is caspase 8 activation at The caspases implicated in apoptosis are currently di-
the cytosolic face of the receptor, but in Bax-initiated vided into initiators and executioners (Figure 3). The
death, the signal is integrated inside the cell, resulting exact order of the executioners and the place of other
in a death pathway that is caspase-independent, and a caspases in the pathway are still controversial, but at
parallel apoptosis pathway that is completely depen- least in the Fas pathway, signaling of death is transmit-
dent on caspases for its accurate outcome. Caspases ted in part by sequential caspase activations. In regard
are not the only enzymes that participate in apoptosis, to the order of caspases in apoptotic pathways, there
since nucleases and protein kinases may also partici- is a valuable lesson to be learned from the caspase 3
pate, but they are absolutely required for the accurate knockout mouse, which has a profound developmental
and limited proteolytic events that typify this type of pro- defect (Kuida et al., 1996). Mice frequently die in utero,
grammed cell death. and those that survive to birth live only a few days with
brains twice the normal volume, due to a large number
of supernumerary cells that presumably failed to die
during neuronal development. One way to interpret this
result is that some forms of developmentally pro-
grammed cell death may utilize executioners (in this
case caspase-3) as initiators of an apoptotic pathway.
This adds a cautionary note to the common impression
that all apoptotic pathways utilize caspases in the same
order.
Why have such a complex network in place to kill a
cell when all that is really needed is to turn off a crucial
housekeeping gene? Presumably, having necrotic cells
around is dangerous, and the apoptotic response is thus
a mechanism to dismantle cells for disposal in a way
that does not compromise the rest of the organism. It
therefore becomes important to determine whether the
observed caspase-mediated cleavages are a vital part
of the apoptotic program, or just bystander events ofFigure 2. Human Caspase Family Relationships
no direct significance. The answer to this question is
Alignment of the catalytic domains demonstrates evolutionary rela-
still open, but it is instructive to note that proteins tar-tionships between the caspases that are mirrored to a variable ex-
geted for cleavage by caspases during apoptosis aretent by their substrate specificity groupings (Thornberry et al., 1997).
The scale is in Myr, with an arbitrary cutoff at 50. involved in RNA splicing, DNA repair, and scaffolding
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of the cytosol and nucleus. Once the decision to die
is made, specific mechanisms must be terminated to
prevent futile attempts at repair. Before the dying cell
can be packaged for endocytosis, it must bedismantled.
Superimposed on this dismantling issue are the crucial
observations that executioner caspases activatecellular
proteins, with a recent example being the description
of a protein whose cleavage is required for induction of
DNA fragmentation (Liu et al., 1997). Consequently,
some of the most informative advances in future cell
death research will undoubtedly be the discovery of the
key proteins activated by caspases during execution.
Figure 4. Intervention Points on the Apoptotic PathwayThe point of commitment in pathways initiated by cell
Though usually studied following Fas ligation, the pathway is alsosurface death receptors is evident. Receptor clustering
engaged through activation of caspase zymogens by granzyme B
results in apical caspase activation to generate the first and, hypothetically, other ectopic proteases. Once activated, the
proteolytic signal, though the mechanism is far from caspases are sensitive to inhibition by the viral products CrmA and
clear. The point of commitment in other pathways is still p35, and perhaps more significantly from the point of normal
reglation, by endogenous inhibitors such as XIAP. The pro- anduncertain, but it has been suggested to encompass a
anti-apoptotic proteins of the Bcl2/Bax family do not directly affectcusp at which the rate of damage outstrips the ability
caspase activity, and are thought to intervene upstream of the exe-of the cell to repair itself (Martin and Green, 1995). Thus,
cutioner caspases.
low levels of damage beyond the repair ability of the
cell result in post-mitotic arrest, and the cell lives. More
adopted by viruses in their attempt to elude the re-severe damage, integrated by the apostat (Figure 3),
sponse of the cell to the infectious insult (Figure 4). Thus,results in transduction of a death signal that likely acti-
much of our grasp of thepivotal role played by proteasesvates the executioners. The identity of the activator is
in apoptosis and cytokine activation comes from under-unknown, but clues to its identity come from genetic and
standing that the pox virus protein CrmA and the bacu-biochemical dissection of cell death in the nematode
lovirus protein p35 specifically target caspases. TheCaenorhabditis elegans, which serves as an elegant
main target for CrmA in context of a cowpox virus infec-model of apoptosis in higher organisms. In this primitive
tion is probably caspase 1, enabling the virus to abro-metazoan, the cell death promoter Ced4 is required to
gate IL-1b and IL-18 production in infected cells, andactivate the effector caspase Ced3 (Chinnaiyan et al.,
also possibly caspase 8 for which the inhibitor demon-
1997), and so the human counterpart of Ced4 would
strates high potency. CrmA binds other caspases too
presumably be a required component of the apostat.
weakly to directly affect the execution phase of apop-Regulation of Activity
tosis. In contrast, p35 has a much broader range, and
Since apical caspases transmit signals to executioners
although its natural targets are not in mammalian cells,
by cleaving zymogen inter-domain linkers, it is reason-
it has the ability to terminate activity of almost all cas-
able that other proteaseswould beable to activatedeath
pases. Interestingly, no homologs of p35 are known in
by the same mechanism. Indeed, this strategy has been
mammals, and though mammals possess many homo-
adopted by the cytotoxic cell protease granzyme B, logs of the serpin CrmA, none of them seem to be tar-
which is the only other mammalian protease that shares geted against caspases. So far, the only demonstrated
the caspase primary specificity for Asp. This protease caspase inhibitor endogenous to mammals is human
is able to activate most caspase zymogens, though sig- X-linked IAP (XIAP), a member of a family of similar
nificantly not caspase 1, by cleaving at the interdomain proteins found throughout metazoans, and first identi-
linker to engage the endogenous cascade following its fied in baculovirus. It is far from clear why cells that
delivery from cytotoxic cells to sensitive targets (re- have committed to apoptosis would need an inhibitor, so
viewed by Zhivotovsky et al., 1997). More remarkable is presumably XIAP, which seems to be targeted against
the recent demonstration that proteases without speci- caspases 3 and 7 (Deveraux et al., 1997), serves to
ficity for Asp are able to activate caspase zymogens at regulate adventitious proteolysis before it has reached
alternate sites in the linker region, at least in vitro (Zhou the catastrophic threshold.
and Salvesen, 1997). It seems that the linker segment Challenges and Potential Therapy
between the large and small subunits is an unusually The discovery of caspases has proceeded well ahead
susceptible interdomain connector designed to be uti- of our understanding of their place in the transmission
lized for rapid proteolysis. Normal caspase zymogen of cellular inflammatory and apoptotic signals. One of
activation takes place at conserved Asp residues, but the greatest challenges facing us now is to determine
the proteolytic sensitivity of the caspase interdomain how the regulation of caspase activity and activation is
link may allow non-Asp-specific proteases such as handled, and how cleavage of proteins leads to apop-
those from lysosomes or viruses to engagethe apoptotic tosis. Given the restricted substrate specificity, it is al-
apparatus under pathological conditions. Perhaps this most certain that caspases and their substrates co-
explains the observation that injection of seemingly non- evolved during the course of metazoan radiation. In this
specific proteases into cells can result in apoptosis (Wil- context, a close investigation of the recognition of
liams and Henkart, 1995). known protein substrates by caspases will likely stimu-
late the discovery of additional key substrates in bothNot surprisingly, inhibition of caspases is a strategy
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Liu, X., Zou, H., Slaughter, C., and Wang, X. (1997). Cell 89, 175±184.the proinflammatory and apoptotic branches of the
Martin, S.J., and Green, D.R. (1995). Cell 82, 349±352.network.
Nicholson, D.W. (1996). Nat. Biotechnol. 14, 297±301.The other major challenge is to apply knowledge of
the caspase network to therapy. Much of the early work Srinivasula, S.M., Ahmad, M., Fernandes-Alnemri, T., Litwack, G.,
andAlnemri, E.S. (1996). Proc. Natl. Acad.Sci. USA 93,14486±14491.on caspase 1 was conducted in pharmaceutical compa-
Talanian, R.V., Quinlan, C., Trautz, S., Hackett, M.C., Mankovich,nies that reasoned that prevention of proinflammatory
J.A., Banach, D., Ghayur, T., Brady, K.D., and Wong, W.W. (1997).cytokine activation would be therapeutic for inflamma-
J. Biol. Chem. 272, 9677±9682.tory disease. In this context, it is heartening to see that
Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z.,the caspase 1 knockout mouse has a complete absence
Beidler, D.R., Poirier, G.G., Salvesen, G.S., and Dixit, V.M. (1995).of IL-1 and IL-18 activity (Ghayur et al., 1997; Gu et al.,
Cell 81, 801±809.
1997) but develops normally (Kuida et al., 1996). Taken
Thompson, C.B. (1995). Science 267, 1456±1462.
together with the somewhat restricted extended sub-
Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M., Timkey,strate specificity of the caspase 1 branch of the family
T., Garcia-Calvo, M., Houtzager, V.M., Nordstrom, P.A., Roy, S.,
(Figure 2), this bodes well for targeting by synthetic Vaillancourt, J.P., et al. (1997). J. Biol. Chem. 272, 17907±17911.
protease inhibitors without interfering with essential Williams, M.S., and Henkart, P.A. (1995). J. Immunol. 153, 4247±
apoptotic functions, at least in the short term. Therapeu- 4255.
tic intervention in apoptosis would also be beneficial Xiang, Q., Chao, D.T., and Korsmeyer, S.J. (1996). Proc. Natl. Acad.
since inappropriate increases in cell death have been Sci. USA 93, 14559±14563.
reported in AIDS, neurodegenerative disorders, and Zhivotovsky, B., Burgess, D.H., Vanags, D.M., and Orrenius, S.
ischemic injury; and a decrease in normal cell deaths is a (1997). Biochem. Biophys. Res. Commun. 230, 481±488.
characteristic of cancer (Thompson, 1995). A significant Zhou, Q., and Salvesen, G.S. (1997). Biochem. J. 324, 361±364.
problem in the development of antidegenerative drugs
is the potential toxic effect due to abrogation of normal
(homeostatic) apoptosis in the human adult, which ac-
counts for over 1011 cell deaths per day. Given this, the
first generation of caspase inhibitors are likely to be
used only in acute settings such as the salvage of cells
destined to die by apoptosis following stroke or myocar-
dial ischemia.
While the goal of treating acute degenerative diseases
is to prevent unwanted death, the major challenge in
treating cancer is to kill cells that have become resistant
to available chemotherapy. Since the failure to undergo
apoptosis is associated with drug resistance, directacti-
vation of caspases in cancer cells may be an effective
strategy to kill the resistant cells. Obviously, for such
an approach to be practical the caspase activator thera-
peutics should be selective for cancer cells, utilizing
specific properties of the oncogenic state (Fearnhead
et al., 1997). Thus, the long-term challenge in basic re-
search is to understand the course of caspase activity
during animal development, homeostasis, and pathol-
ogy; and in therapy to develop drugs targeted to specific
cells and tissues to block acute and chronic disease
through intervention in the caspase network.
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